The Effect of Evolocumab Alone and in Combination With Atorvastatin on Lipid Profile

Abstract

The aim: In this study, we try to investigate whether evolocumab or its combination with atorvastatin has potent effect on lipid profile? Materials and methods: Forty local domestic male rabbits were included in this study, and categorized into four group, two untreated group (nohypercholostermic and untreated hypercholostermic) and treated groups (evolocumab treated group at dose 6.1mg/kg/2Wk and atorvastatin treated group at dose 3.5 mg/kg/day),the blood samples were analyzed at base line and after 5week and at the end of the study after 10 weeks for lipid profile by standard enzymatic methods. Results: The serum levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C),were increased after 10 weeks of administration of the atherogenic diet significantly (p<0.05) as compared with other groups (group I: 61.19 ± 14, group ΙΙ: 1301 ± 443, group ΙΙΙ 41.01 ± 5.81: 280 ± 50, group ΙV: 190 ± 38 group Ι: 46 ± 15.0, group ΙΙ: 256.0 ± 24.0, group ΙΙΙ: 101.0±28, group ΙV: 48.18 ± 15.27, group Ι: 29±14.50, group ΙΙ: 929±251.0, group ΙΙΙ: 283.0±36, group ΙV: 209.0±33mg/dl) respectively while the levels of high-density lipoprotein cholesterol (HDL-C) decrease (18.0±4.1 to 15.0±3.0mg/dl). Compared with evolocumab monotherapy, combination of evolocumab and atorvastatin reduce serum level of total cholesterol, triglyceride and low density lipoprotein more than that of evolocumab. Conclusions: Preproteins convert as esubtilisin/kexin type 9 inhibitor regulates the serum levels of lipid and cholesterol by lowering LDL-C, and the results also indicate that combination of evolocumab and atorvastatin are more potent in lowering the lipid profile and then reduce progression of atherosclerosis than evolocumab alone in rabbits suggesting that this combination might be beneficial for treatment of atherosclerosis.

Impact of Glucagon-Like Peptide 1 Receptor Agonists on Biochemical Markers of the Initiation of Atherosclerotic Process

“…Researchers managed to observe similar effects in relation to one of the newest types of lipid-lowering therapy, i.e., therapy with PCSK-9 inhibitors. In the case of Il-1β, the first study appeared in May 2023, which proved the relationship between the use of evolocumab and the reduction in the concentration of these proinflammatory interleukins and inhibition of the inflammatory process [25]. With regard to TNFα, the first article confirming such a decrease in the concentration of this cytokine after the use of alirocumab was the work prepared by our team in 2022 [26].…”

Expression of pro- and anti-inflammatory cytokines during anti-proprotein convertase subtilisin/kexin type 9 therapy in patients with statin-resistant familial hypercholesterolemia

“…Interestingly, PCSK9i has been described to lower TLR expression, as well as pro-inflammatory mediators IL-17, IL-1β, ICAM and VCAM, which parallels the reduction of arterial intimal thickness and atherogenic plaques; with a higher effect as compared to statins, in animal model. While such anti-inflammatoty effects may be potientiated by the combination of PCSK9i—statins ( 30 ).…”